Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2026
Optune Pax receives approval in Japan
Optune Pax received approval from Japan's Ministry of Health, Labour and Welfare for use in adult patients with unresectable locally advanced pancreatic cancer, in combination with gemcitabine and nab-paclitaxel.
2026
Novocure and Verastem Oncology enter clinical-trial collaboration
Novocure entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate TTFields therapy with chemotherapy and Verastem's investigational VS-7375 for locally advanced pancreatic cancer.
2021
FDA approves Novocure application to initiate KEYNOTE-B36 trial
Novocure reported that the U.S. FDA approved its investigational device exemption application to initiate the KEYNOTE-B36 phase 2 pilot trial studying TTFields with pembrolizumab in first-line non-small cell lung cancer.
2020
Novocure reports first-quarter 2020 results
Novocure reported first-quarter 2020 financial results, including net revenues of $101.8 million, up 39 percent from the first quarter of 2019, and net income of $4.0 million.